Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech clinical trial

Insilico Rentosertib Phase III IPF First Patient

Analysis based on 6 articles · First reported Sep 10, 2026 · Last updated Sep 10, 2026

Sentiment
25
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The milestone reinforces Insilico Medicine's position as a leader in AI-driven drug discovery and could support its share price, which trades on the Hong Kong Stock Exchange, by advancing the first generative AI-discovered drug into late-stage clinical testing. Positive sentiment may spill over to the broader AI-biotech sector and Insilico's collaboration partners, though the drug remains investigational and approval is reportedly three to four years away, limiting near-term revenue impact.

biotechnology pharmaceuticals artificial intelligence

Insilico Medicine announced on September 9-10, 2026 that it has dosed the first patient with Rentosertib (ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial for idiopathic pulmonary fibrosis (IPF), at United Medical College Hospital, while Shanghai Pulmonary Hospital enrolled its first patient on the same day. The trial is a prospective, multi-center, randomized, double-blind, placebo-controlled, parallel-group study evaluating once-daily Rentosertib over 52 weeks, expected to enroll 320 participants across 47 centers in China, with the primary endpoint being the annual rate of decline in forced vital capacity. The study is led by Professor Zuojun Xu of United Medical College Hospital as Leading Principal Investigator, with Academician Nanshan Zhong and President Chang Chen as Co-Leading Principal Investigators. Rentosertib is described as the world's first drug candidate discovered and developed using generative AI, targeting TNIK, a fibrosis-related pathway identified through AI-driven discovery. Earlier Phase IIa results showed promising dose-dependent improvements in lung function, and the Phase III study aims to validate these findings in a larger cohort over a longer duration. Regulatory approval could reportedly take three to four years under favorable conditions. Insilico also reported first-half 2026 revenue of approximately $106 million, a 287% year-over-year increase, and its first profitable half-year since listing, with adjusted net profit exceeding $51 million, driven by collaborations with partners including Eli Lilly and Company, Laboratoires Servier, Takeda Pharmaceutical Company, SK Biopharmaceuticals, Qilu Pharmaceutical, Hygeia Therapeutics, CMS, and Tenacia. The U.S. United States — Food and Drug Administration granted Orphan Drug Designation to Rentosertib for IPF in February 2023. Insilico Medicine is listed on the Hong Kong Stock Exchange under stock code 3696.

95 Insilico Medicine dosed first patient
60 Insilico Medicine reported revenue
45 Insilico Medicine nominated candidates
40 Shanghai Pulmonary Hospital enrolled first patient
priv
Insilico Medicine is the central actor, dosing the first patient in the Phase III trial of Rentosertib and reporting strong revenue growth and profitability. The milestone strengthens its AI-driven drug discovery narrative and could positively affect its Hong Kong-listed shares.
Importance 100.0 Sentiment 40.0
priv
United Medical College Hospital is the site where the first patient was dosed and is led by the trial's Leading Principal Investigator, Professor Zuojun Xu. Its involvement underscores its role in advancing clinical research for IPF.
Importance 60.0 Sentiment 10.0
priv
Shanghai Pulmonary Hospital enrolled its first patient on the same day and its President, Chang Chen, serves as a Co-Leading Principal Investigator. This highlights the hospital's participation in the pivotal trial.
Importance 50.0 Sentiment 10.0
cnt
China is the location for the Phase III trial, with 47 centers expected to enroll 320 participants. The event highlights China's role in advanced AI-driven clinical research.
Importance 40.0 Sentiment 5.0
exch
The Hong Kong Stock Exchange is where Insilico Medicine is listed under stock code 3696, and the trial milestone may influence trading activity. The exchange itself is not directly affected.
Importance 30.0 Sentiment 5.0
govactor
The United States — Food and Drug Administration granted Orphan Drug Designation to Rentosertib for IPF in February 2023, a regulatory milestone that supports the drug's development. The current event does not involve new FDA action.
Importance 20.0 Sentiment 0.0
curr
The Hong Kong — Hong Kong dollar is the currency in which Insilico Medicine's shares trade on the Hong Kong Stock Exchange. The event may affect trading volumes but has no direct impact on the currency.
Importance 20.0 Sentiment 0.0
stock
Eli Lilly and Company is mentioned as one of Insilico's collaboration partners, contributing to Insilico's contract value and revenue growth. The event has minimal direct impact on Eli Lilly.
Importance 15.0 Sentiment 5.0
priv
Laboratoires Servier is listed as a collaboration partner of Insilico Medicine, supporting its commercial model. The event has minimal direct impact on Laboratoires Servier.
Importance 15.0 Sentiment 5.0
stock
Takeda Pharmaceutical Company is mentioned as a partner in Insilico's out-licensing and co-development deals. The event has minimal direct impact on Takeda.
Importance 15.0 Sentiment 5.0
stock
SK Biopharmaceuticals is listed among Insilico's collaboration partners. The event has minimal direct impact on SK Biopharmaceuticals.
Importance 10.0 Sentiment 5.0
priv
Qilu Pharmaceutical is mentioned as a partner in Insilico's collaborations. The event has minimal direct impact on Qilu Pharmaceutical.
Importance 10.0 Sentiment 5.0
priv
Hygeia Therapeutics is listed as a collaboration partner of Insilico Medicine. The event has minimal direct impact on Hygeia Therapeutics.
Importance 10.0 Sentiment 5.0
priv
CMS is mentioned as one of Insilico's partners. The event has minimal direct impact on CMS.
Importance 10.0 Sentiment 5.0
priv
Tenacia is listed as a collaboration partner of Insilico Medicine. The event has minimal direct impact on Tenacia.
Importance 10.0 Sentiment 5.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.